title: Systemic thrombin generation in cancer patients is correlated with extrinsic pathway activation.
abstract: Since the first report by Trousseau in 1865, several experimental and clinical studies have established that activation of coagulation is common in cancer. However, the biochemical basis of the activation of coagulation in cancer patients is still not completely understood. The current most accepted opinion is that initiation of coagulation in malignancy is driven primarily by activation of the extrinsic (tissue factor-dependent) pathway. In order to further prove that such a pathogenetic mechanism is actually involved in cancer patients, we correlated the plasma levels of activated factor VIIa (FVIIa), which represent a very small fraction of plasma FVII, with some well-established markers of systemic thrombin generation. Circulating FVIIa was measured using a prothrombin time-based assay that employs a truncated form of human recombinant tissue factor, while plasma levels of the thrombin-antithrombin complex, the prothrombin fragments 1 + 2 and D-dimer were determined by commercially available ELISA kits. The study was carried out in 37 patients with different types of cancer and 20 healthy controls. Plasma levels of FVIIa were significantly increased while those of FVII antigen (FVIIag) were decreased in cancer patients compared with controls. Furthermore, the FVIIa/ VIIag ratio was more than two-fold higher in cancer patients than in controls. In addition, an excess of thrombin generation was observed in cancer patients. Interestingly, a positive correlation between the FVIIa/VIIag ratio and the plasma levels of either D-dimer (Spearman's r = 0.325; P = 0.027) or prothrombin fragments 1 + 2 (r = 0.309; P = 0.034) was observed in cancer patients. In conclusion, our study further supports the hypothesis that the tissue factor/VIIa complex is the main determinant of coagulation activation in cancer patients. Large clinical studies will be necessary to determine whether FVIIa and the FVIIa/VIIag ratio are useful prognostic factors of thromboembolic events in cancer patients.
authors.affiliation: Istituto di Medicina Interna e di Medicina Vascolare, Università degli Studi di Perugia, Italy. Vincenzo@unipg.it
authors.forename: V
authors.initials: V
authors.lastname: Costantini
authors.forename: P
authors.initials: P
authors.lastname: De Monte
authors.forename: A O
authors.initials: AO
authors.lastname: Cazzato
authors.forename: A M
authors.initials: AM
authors.lastname: Stabile
authors.forename: R
authors.initials: R
authors.lastname: Deveglia
authors.forename: E
authors.initials: E
authors.lastname: Frezzato
authors.forename: M C
authors.initials: MC
authors.lastname: Paolucci
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D015415:Biomarkers; D001777:Blood Coagulation; D001780:Blood Coagulation Tests; D001943:Breast Neoplasms / Q000097:blood; D005260:Female; D005770:Gastrointestinal Neoplasms / Q000097:blood; D006801:Humans; D008175:Lung Neoplasms / Q000097:blood; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000097:blood*; D013917:Thrombin / Q000032:analysis / Q000096:biosynthesis*
chemical_list: D015415:Biomarkers; D013917:Thrombin